Biohaven’s Oral CGRP Inhibitor Nurtec ODT Approved In The US For Acute Migraine
Executive Summary
The fast-dissolving tablet will launch in early March. Its list price is not available but based on pricing for Allergan’s oral anti-CGRP Ubrelvy, ICER has said Biohaven’s rimegepant is likely to be cost-effective.
You may also be interested in...
Pfizer To Put Big Marketing Muscle Behind Migraine With Biohaven Purchase
Pfizer’s $11.6bn acquisition of the company brings it full rights to the oral migraine drug Nurtec ODT and nasal spray zevegepant, with aims to build a $6bn migraine franchise.
AbbVie Qulipta Shows Benefit In Severely Afflicted Chronic Migraine Patients
The drug could see a competitive edge over other anti-CGRP agents with new chronic migraine data plus convenience as an oral drug and potential for combination with Botox.
Biohaven’s Q3 Nurtec ODT Sales Indicate Gains Across Multiple Launch Parameters
The company pre-announced $136m in third quarter sales, beating analyst consensus and signaling both increased oral CGRP inhibitor market share and improved per-prescription net revenue.